HS
Heike Susanne Van Dawen
About Heike Susanne Van Dawen
Data last updated:
Heike Susanne Van Dawen is a Director at Fresenius Kabi Oncology Limited (since 2024). The company operates in Pharma. Fresenius Kabi Oncology Limited reported revenue of ₹848 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Fresenius Kabi Oncology Limited U24231DL2003PLC119441 | Director | 04 Jun 2024 | 2003 | ₹848 Cr (FY 2025) | Active |
Board colleagues of Heike Susanne Van Dawen
| Name | DIN | Company | Designation |
|---|---|---|---|
| Arvind Kumar Sharma | 08144338 | Fresenius Kabi Oncology Limited | Managing Director |
| Eduardo Ricardo Dos Santos Montanha | 08158265 | Fresenius Kabi Oncology Limited | Additional Director |
| Maximilian Alexander Bohmer | 10279854 | Fresenius Kabi Oncology Limited | Director |
| Nikhil Kulshreshtha | 07178027 | Fresenius Kabi Oncology Limited | Nodal Officer |
| Nikhil Kulshreshtha | Fresenius Kabi Oncology Limited | Company Secretary | |
| Rahul Sharma | Fresenius Kabi Oncology Limited | Cfo |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Heike Susanne Van Dawen
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Heike Susanne Van Dawen
Heike Susanne Van Dawen currently holds 1 directorship: Fresenius Kabi Oncology Limited (Director, since 04 Jun 2024, revenue ₹848 Cr (FY 2025)).
Heike Susanne Van Dawen was first appointed on 04 Jun 2024 as Director at Fresenius Kabi Oncology Limited.
The current boards of Heike Susanne Van Dawen's companies include Arvind Kumar Sharma (Fresenius Kabi Oncology Limited), Eduardo Ricardo Dos Santos Montanha (Fresenius Kabi Oncology Limited), Maximilian Alexander Bohmer (Fresenius Kabi Oncology Limited), Nikhil Kulshreshtha (Fresenius Kabi Oncology Limited), Nikhil Kulshreshtha (Fresenius Kabi Oncology Limited), Rahul Sharma (Fresenius Kabi Oncology Limited).